news
FDA approves first biosimilar for the treatment of cancer
Mvasi, a biosimilar to the cancer drug Avastin, is approved for certain colorectal, lung, brain, kidney and cervical cancers…
List view / Grid view
Lung cancer
news
Cancer Research UK launches trial to test new drug
A clinical trial to test a new cancer drug in patients with advanced solid tumours, launches in four centres across the UK...
news
Gold nanoparticles raise hopes for cancer treatments
Researchers have discovered properties of the precious metal that allow catalytic abilities to be accessed in living things without any side effects...
news
Novartis combination targeted therapy receives FDA approval
The FDA has approved Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) to treat patients with metastatic non-small cell lung cancer.
news
FDA approves Roche’s lung cancer companion diagnostic
6 June 2017 | By Niamh Marriott, Junior Editor
The FDA have approved Roche’s VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC) patients...
news
FDA approves expanded use of Novartis’ lung cancer drug Zykadia
30 May 2017 | By Niamh Marriott, Junior Editor
The US Food and Drug Administration (FDA) approved the expanded use of Novartis’ Zykadia (ceritinib) to include patients with NSCLC...
news
FDA allows novel inhaled lung cancer treatment to commence clinical trials
25 April 2017 | By Niamh Marriott, Junior Editor
North Carolina based Biomarck Pharmaceuticals has received FDA allowance to begin human trials for their patented compound BIO-11006, for adults with lung cancer.
news
Merrimack initiates Phase 1 study of MM-310 in solid tumours
29 March 2017 | By Niamh Marriott, Junior Editor
Merrimack Pharmaceuticals have enrolled its first patient in a Phase 1 study of MM-310 in solid tumours.
news
NICE does not recommend Merck’s lung cancer drug
2 March 2017 | By Niamh Marriott, Digital Editor
NICE has published draft guidance which does not recommend Keytruda, also known as pembrolizumab, for untreated PD-L1-positive metastatic lung cancer...
news
Scancell preparing SCIB2 for clinical study in lung cancer
13 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Scancell intends to develop its SCIB2 ImmunoBody for the treatment of non-small cell lung cancer (NSCLC) in combination with a checkpoint inhibitor...
news
EU approval for Pfizer’s non-small cell lung cancer drug
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The drug exhibited marked anti-tumour activity in patients with ROS1-positive advanced NSCLC and met its primary endpoint of ORR. Tumours were tested for ROS1 rearrangements by laboratory-developed break-apart fluorescence in situ hybridization (FISH) (96%) or real-time polymerase chain reaction (RT-PCR) (4%) assay...
news
NICE recommends Pfizer’s lung cancer drug after price drop
18 August 2016 | By The National Institute for Health and Care Excellence (NICE)
When initially reviewed, the committee concluded that the drug was too expensive compared to the current standard of care. Pfizer submitted further evidence, including a new patient access scheme that provided the drug at a lower price alongside revised analyses, which the committee then concluded could now be considered value…
news
Unsuccessful and disappointing clinical trials for AstraZeneca’s lung cancer drug
9 August 2016 | By AstraZeneca
The results showed that the trial did not meet its primary endpoint of progression-free survival (PFS), and selumetinib did not have a significant effect on overall survival (OS). The adverse event profiles for selumetinib and docetaxel were consistent with those seen previously...
news
PharmaMar initiates a phase III ATLANTIS study for small cell lung cancer
2 August 2016 | By PharmaMar
PharmaMar announced the start of a pivotal Phase III ATLANTIS study evaluating efficacy and safety of PM1183 (lurbinectedin) in combination with doxorubicin versus topotecan or the combination VCR (cyclophosphamide, adriamicine (doxorubicin) and vincristine) in patients with small cell lung cancer after the failure of one prior platinum-containing line.
news
CHMP positive opinion for Keytruda in NSCLC
27 June 2016 | By Victoria White, Digital Content Producer
The CHMP has recommended approval of Keytruda for the treatment of locally advanced or metastatic NSCLC in adults whose tumours express PD-L1...
